Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT) Eligible patients had measurable disease, Eastern ...
WALTHAM, Mass. and BOULDER, Colo., Oct. 14, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (COGT) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...
Bottom Line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Bent bone dysplasia (BBD) is a perinatal-lethal skeletal disorder caused by pathogenic FGFR2 mutations that disrupt bone formation, leading to bent long bones, osteopenia, and craniosynostosis. Bent ...
Notably, Insilico’s self-developed Chemistry42 played a crucial role in this research by generating the pyrrolopyrazine carboxamide core as a starting point for further molecular design. Moreover, ...
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are ...
ALLELIC TWINS: Jackson-Weiss and Crouzon syndromes are both caused by FGFR2 mutation, notes Johns Hopkins researcher Ethylin Jabs. E.W. Jabs, X. Li, A.F. Scott, G ...
Cogent Biosciences, Inc. announced strong preclinical data from four of its therapeutic pipeline programs during the AACR 2025 Annual Meeting in Chicago, showcasing its work on precision therapies for ...
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback